These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37255929)

  • 21. Promises and challenges of senolytics in skin regeneration, pathology and ageing.
    Pils V; Ring N; Valdivieso K; Lämmermann I; Gruber F; Schosserer M; Grillari J; Ogrodnik M
    Mech Ageing Dev; 2021 Dec; 200():111588. PubMed ID: 34678388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.
    Al-Mansour F; Alraddadi A; He B; Saleh A; Poblocka M; Alzahrani W; Cowley S; Macip S
    Aging (Albany NY); 2023 Mar; 15(7):2373-2394. PubMed ID: 36988504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration.
    Wu Y; Shen S; Shi Y; Tian N; Zhou Y; Zhang X
    Front Bioeng Biotechnol; 2022; 10():823945. PubMed ID: 35309994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of cellular senescence in skin ageing: A notion of mosaic and therapeutic strategies.
    Toutfaire M; Bauwens E; Debacq-Chainiaux F
    Biochem Pharmacol; 2017 Oct; 142():1-12. PubMed ID: 28408343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Advances in Senotherapeutics Delivery.
    Choi JY; Yee SF; Tchangalova T; Yang G; Fisher JP
    Tissue Eng Part B Rev; 2022 Dec; 28(6):1223-1234. PubMed ID: 35451328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Senolytics in the treatment of diabetic retinopathy.
    Hassan JW; Bhatwadekar AD
    Front Pharmacol; 2022; 13():896907. PubMed ID: 36091769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Senescence under appraisal: hopes and challenges revisited.
    Davan-Wetton CSA; Pessolano E; Perretti M; Montero-Melendez T
    Cell Mol Life Sci; 2021 Apr; 78(7):3333-3354. PubMed ID: 33439271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The costs and benefits of senotherapeutics for human health.
    Raffaele M; Vinciguerra M
    Lancet Healthy Longev; 2022 Jan; 3(1):e67-e77. PubMed ID: 36098323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular senescence and senolytics: the path to the clinic.
    Chaib S; Tchkonia T; Kirkland JL
    Nat Med; 2022 Aug; 28(8):1556-1568. PubMed ID: 35953721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases.
    Lagoumtzi SM; Chondrogianni N
    Free Radic Biol Med; 2021 Aug; 171():169-190. PubMed ID: 33989756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing.
    Dhokia V; Albati A; Smith H; Thomas G; Macip S
    Biochem Soc Trans; 2024 Jun; ():. PubMed ID: 38940746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photoactivatable senolysis with single-cell resolution delays aging.
    Shi D; Liu W; Gao Y; Li X; Huang Y; Li X; James TD; Guo Y; Li J
    Nat Aging; 2023 Mar; 3(3):297-312. PubMed ID: 37118423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging.
    Rani A; Bean L; Budamagunta V; Kumar A; Foster TC
    Front Aging Neurosci; 2024; 16():1384554. PubMed ID: 38813533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Senolytic therapy ameliorates renal fibrosis postacute kidney injury by alleviating renal senescence.
    Li C; Shen Y; Huang L; Liu C; Wang J
    FASEB J; 2021 Jan; 35(1):e21229. PubMed ID: 33368613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Use of Senolytics for Pharmacological Targeting of Precancerous Lesions.
    Saleh T; Carpenter VJ
    Mol Pharmacol; 2021 Dec; 100(6):580-587. PubMed ID: 34544896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
    Justice JN; Nambiar AM; Tchkonia T; LeBrasseur NK; Pascual R; Hashmi SK; Prata L; Masternak MM; Kritchevsky SB; Musi N; Kirkland JL
    EBioMedicine; 2019 Feb; 40():554-563. PubMed ID: 30616998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular Senescence in Cardiovascular Diseases: From Pathogenesis to Therapeutic Challenges.
    Li D; Li Y; Ding H; Wang Y; Xie Y; Zhang X
    J Cardiovasc Dev Dis; 2023 Oct; 10(10):. PubMed ID: 37887886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular Senescence in Idiopathic Pulmonary Fibrosis.
    Kellogg DL; Kellogg DL; Musi N; Nambiar AM
    Curr Mol Biol Rep; 2021; 7(3):31-40. PubMed ID: 34401216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Senolytics and cell senescence: historical and evolutionary perspectives.
    Finch CE
    Evol Med Public Health; 2024; 12(1):82-85. PubMed ID: 38757096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National Institute on Aging Workshop: Repurposing Drugs or Dietary Supplements for Their Senolytic or Senomorphic Effects: Considerations for Clinical Trials.
    Romashkan S; Chang H; Hadley EC
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):1144-1152. PubMed ID: 33528569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.